Document is current
Any future updates will be listed below
-
Authors
Hamada, Naoki
Tokunaga, Shoji
Yanagihara, Toyoshi
Tsubouchi, Kazuya
Ichiki, Katsuyuki
Takata, Shohei
Ishii, Hiroshi
Kitasato, Yasuhiko
Okamoto, Masaki
Yatera, Kazuhiro
Kawasaki, Masayuki
Yoshida, Makoto
Maeyama, Takashige
Fujita, Masaki
Mashimoto, Ayano
Furuyama, Kazuto
Torii, Ryo
Suzuki, Kunihiro
Mizuta, Yuichi
Tobino, Kazunori
Harada, Eiji
Yabuuchi, Hidetake
Okamoto, Isamu
Nakanishi, Yoichi
-
Funding
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology: the broad-area, network-based project to drive clinical research at Kyushu University Hospital
The Diffuse Lung Diseases Research Group from the Ministry of Health, Labor and Welfare, Japan.
Boehringer Ingelheim Japan
- License Information
-
More Information
Article History
Received: 19 July 2025
Accepted: 29 September 2025
First Online: 5 November 2025
Declarations
:
: This prospective, multicenter, observational study was approved by the Institutional Review Board of Kyushu University (#25–135, August 23, 2013; #555-00, August 27, 2013; #2021 − 362, December 13, 2021) and by the institutional review boards of all participating hospitals, in accordance with the Declaration of Helsinki (2013 revision). Written informed consent was obtained from all patients prior to study enrollment.
: NH, TY, HI, MO, KY, KTobino, KY, and EH has received personal fee from Boehringer Ingelheim. IO has received personal fee from Chugai pharma, Ono Pharma, Taiho Pharma, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Takeda Pharma, Novartis Pharma, Daiichi Sankyo. NH, TY, KTsubouchi, MO, KY and MY has received research funding from Boehringer Ingelheim. IO has received research funding from Daiichi Sankyo, Bristol-Myers Squib, Chugai Pharma, MSD Oncology, Eli Lilly, AstraZeneca, Taiho Pharma, Boehringer Ingelheim and Ono Pharma. Boehringer Ingelheim had no role in the design, analysis or interpretation of the results in this study. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to Boehringer Ingelheim substances, as well as intellectual property considerations.
